NAI Sales Jump 23%, But Deepening Losses Reveal Operational Strain

CARLSBAD, Calif. – May 19, 2026 – Natural Alternatives International, Inc. (Nasdaq: NAII) today presented a starkly paradoxical financial picture, announcing that while its net sales surged 23% in the third quarter of fiscal 2026, its net loss nearly doubled, deepening concerns about the company's operational efficiency and path to profitability.

The nutritional supplement formulator and manufacturer reported net sales of $35.5 million for the quarter ending March 31, 2026, a significant increase from the $28.8 million recorded in the same period last year. However, this top-line growth was overshadowed by a net loss of $4.3 million, or $0.72 per share, compared to a $2.2 million loss in the prior year's quarter.

The results highlight a persistent challenge for the company: an inability to translate robust sales growth into bottom-line profit, a trend that has worried investors for several fiscal years.

The Paradox of Growth

The primary engine behind NAI's revenue growth is its private-label contract manufacturing division. Sales in this segment jumped 25% to $33.8 million, driven by increased orders from one of its largest customers and new client acquisitions. For the first nine months of the fiscal year, total net sales are up 13% to $108.0 million.

Despite this momentum, the company's profitability has eroded. The year-to-date net loss stands at $7.2 million, up from $6.4 million in the comparable period of fiscal 2025. According to NAI, the principal cause for the disconnect between rising sales and falling profits is the chronic "underutilization of our factory capacities."

This is not a new issue. An analysis of NAI's recent performance reveals a troubling pattern. The company posted a net loss of $13.58 million for the full fiscal year 2025, even as its private-label manufacturing sales grew 16%. This followed a $7.22 million net loss in fiscal 2024. The last profitable year for the company was fiscal 2023, and since then, weak gross profit margins have plagued its financial statements. Even as new and large customers drive sales, the cost of goods sold has risen steeply, climbing to 98.9% of net sales in the latest quarter, leaving a razor-thin gross profit margin of just 1.1%.

A Strategic Lifeline

In a decisive move to address its financial pressures and fund its turnaround strategy, NAI announced it has secured a new credit facility, replacing its previous arrangement with Wells Fargo. On May 18, the company entered into a new Loan and Security Agreement with Legacy Corporate Lending, LLC.

The new financing package includes an $11.0 million term loan and a revolving working capital line of credit with a maximum capacity of $20.0 million. Management stated the new agreement provides "greater flexibility in working capital and covenant requirements to support our anticipated sales growth."

This move is significant, suggesting the company needed more favorable terms than its previous lender could provide as it navigates this period of operational unprofitability. The fresh capital provides a crucial runway, allowing NAI to continue its operations and invest in growth initiatives while it works to solve its underlying efficiency problems. However, it also increases the company's debt burden, raising the stakes for management to deliver on its promise of a turnaround.

Betting on Innovation

While grappling with manufacturing inefficiencies, NAI is simultaneously making a high-stakes bet on product innovation to secure its future. The company's strategy hinges on revitalizing its proprietary ingredients business, centered on its flagship CarnoSyn® beta-alanine product.

Revenue from CarnoSyn® royalties, licensing, and raw material sales has been a point of weakness, remaining flat in the third quarter and declining 11% year-to-date. To counter this, NAI is aggressively expanding its portfolio with next-generation ingredients.

In his statement, Chairman and CEO Mark A. Le Doux highlighted the launch of TriBsyn® and the recently announced CarnoSyn® 4x. He noted the company is beginning to see market recognition for TriBsyn®, a "paresthesia free beta-alanine with 4x potency," which could have broad applications in foods, beverages, powders, and supplements. The goal is to create products that are more potent and versatile, offering a clear competitive advantage and commanding higher margins than its struggling manufacturing segment.

"We remain committed to restoration of profitability and are actively pursuing multiple paths to that objective," Le Doux stated, emphasizing a focus on expanding the client base to enhance factory utilization while continuing to invest in the CarnoSyn® brand estate. The success of these new, scientifically-backed ingredients is now a critical component of NAI's plan to shift from a high-volume, low-margin manufacturer to a more profitable, innovation-led enterprise.

The road ahead for Natural Alternatives International is complex. While the company projects that sales revenue will continue to increase in the fourth quarter, it also anticipates another net loss for the quarter and the full fiscal year. The executive team is now under immense pressure to leverage its new financial flexibility and innovative product pipeline to finally solve its long-standing operational cost issues. The coming months will be a decisive test of whether NAI can successfully transform its impressive top-line growth into sustainable profitability.